



Ms H Farrant  
CANCER RESEARCH UK & UNIV. COLL. LONDON CANCER TRIALS CENTRE  
90 TOTTENHAM COURT ROAD  
LONDON  
W1T 4TJ  
UNITED KINGDOM

11/12/2012

Dear Ms H Farrant

**THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031**

Our Reference: 20363/0204/001-0035  
Eudract Number: 2004-002197-34  
Product: Mabthera  
Protocol number: 04/Q1104/27  
Substantial Amendment Code Number: Substantial Amendment 29.10.12 (Main Protocol v8.0)

**NOTICE OF ACCEPTANCE OF AMENDMENT**

I am writing to inform you that the Licensing Authority accepts the proposed amendment to your clinical trial authorisation (CTA), received on 08/11/2012.

This amendment may therefore be made.

You are reminded that where it is appropriate, the Ethics Committee should also be notified of amendments.

Yours sincerely,

**Clinical Trials Unit  
MHRA**